| Longitudinal study of socioeconomic factors, stress-related biomarkers, and aggressive prostate cancer |
Kathryn Barry |
University of Maryland, Baltimore |
PLCO |
Jun 17, 2026 |
2026-0158 |
| Multi-population study of serum protein biomarkers and prostate cancer risk |
Sonja Berndt |
National Cancer Institute |
PLCO |
Jun 17, 2026 |
2026-0154 |
| Leveraging antibody responses against transposable elements as a novel immune therapy for ovarian cancer |
Rebecca Lynch |
The George Washington University School of Medicine and Health Sciences |
PLCO |
Jun 17, 2026 |
2026-0096 |
| Exosome-based microRNA Biomarkers for Non-invasive and Early Detection of Colorectal Cancer and Advanced Adenomas |
Ajay Goel |
City of Hope |
PLCO |
Jun 16, 2026 |
2025-0016 |
| Efficient Design and Analysis of Two-Phase Biomarker Studies |
Li Cheung |
National Cancer Institute |
PLCO |
Jun 8, 2026 |
PLCO-2053 |
| Behavioral effects of screening offers |
Ethan Lieber |
University of Notre Dame du Lac |
PLCO |
May 29, 2026 |
PLCO-2044 |
| Estimating the intake of moderation foods and evaluating associations with risk of cancer and mortality |
Kaelyn Burns |
National Cancer Institute |
PLCO |
May 4, 2026 |
PLCO-2045 |
| Wildfire Smoke Exposure and Cancer- and Aging-Related Outcomes in the PLCO Cohort |
Shuguang Leng |
University of New Mexico HSC |
PLCO |
Apr 28, 2026 |
PLCO-2041 |
| Reexamine trial outcomes in PLCO to identify interactions of screening effects with screen results and other covariates (Original Project: PLCO-1091) |
Hormuzd Katki |
American Cancer Society |
PLCO |
Apr 28, 2026 |
PLCO-2043 |
| Continuation of DCPP (PLCO-286/PLCO-287) |
Stephanie Smith-Warner |
Harvard TH Chan School of Public Health |
PLCO |
Apr 27, 2026 |
PLCO-2042 |
| Association between microplastic exposure and risk of never-smoking lung cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial |
Qing Lan |
National Cancer Institute |
PLCO |
Apr 21, 2026 |
2025-0048 |
| Generalizability of the PLCO |
Sarah Robertson |
Dartmouth College |
PLCO |
Apr 20, 2026 |
PLCO-2039 |
| Statistical methods to detect and estimate etiologic heterogeneity in epidemiologic studies |
Anil Chaturvedi |
National Cancer Institute |
PLCO |
Apr 13, 2026 |
PLCO-2038 |
| Developing an All-cancer Risk Model |
Paul Pinsky |
National Institutes of Health |
PLCO |
Apr 13, 2026 |
PLCO-2040 |
| AI-Enabled Opportunistic Detection of Cardiovascular Disease Risk from Chest Radiographs in the PLCO Cohort |
Morteza Naghavi |
HeartLung Technologies |
PLCO |
Mar 30, 2026 |
PLCOI-2034 |
| Integrative Genomic, Histologic, and Spatial Profiling of ClonalHematopoiesis in Lung Cancer |
Janghee Woo |
Emory University |
PLCO |
Mar 30, 2026 |
PLCOI-2024 |
| Pilot study of circulating immune checkpoint proteins in persons with and without cancer |
Kara Michels |
Albert Einstein College of Medicine |
PLCO |
Mar 26, 2026 |
2026-9129 |
| Integrative Analysis of Metabolic Programs Associated with Cancer Risk and Outcomes in the PLCO Cohort |
Blake Rushing |
University of North Carolina at Chapel Hill |
PLCO |
Mar 26, 2026 |
PLCO-2035 |
| Exposomic and Metabolomic Approaches to Understanding Cancer Risk in Females: A Secondary PLCO Study |
Jordan Kuiper |
The George Washington University |
PLCO |
Mar 23, 2026 |
PLCO-2027 |
| Validation of a bladder cancer risk model with lifestyle and environmental risk factors and polygenic risk score in two prospective cohorts. (PLCO-1972 continued) |
Parichoy Pal Choudhury |
American Cancer Society |
PLCO |
Mar 16, 2026 |
PLCO-2033 |
